Valuation: Avalo Therapeutics, Inc.

Market Cap 389M 347M 319M 290M 544M 36.83B 558M 3.81B 1.53B 19.44B 1.46B 1.43B 61.62B P/E 2026 *
-2.56x
P/E 2027 * -2.59x
Enterprise Value -35.18M -31.43M -28.87M -26.22M -49.24M -3.33B -50.48M -345M -139M -1.76B -132M -129M -5.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.16%
Yield 2027 * 0.01%
1 day-0.96%
1 week+7.41%
Current month+1.12%
1 month-51.63%
3 months-59.83%
6 months-47.12%
Current year-60.08%
1 week 7
Extreme 7.0001
7.71
1 month 6.53
Extreme 6.53
15.09
Current year 6.53
Extreme 6.53
24.27
1 year 6.53
Extreme 6.53
24.27
3 years 3.39
Extreme 3.39
34.46
5 years 3.39
Extreme 3.39
7,027.15
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

1,322 0.0025%
30/9/26 Free

Director

1,109 0.0021%
30/9/26 Free

Director

1,352 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%+7.41%-56.51%-70.76% 389M
-2.43%-4.38%+40.32%+55.64% 60.57B
+0.62%+2.58%+20.96%+98.18% 55.51B
+0.61%+0.77%+11.13%+69.42% 55.22B
+1.61%-3.30%+22.77%+33.16% 43.27B
-1.74%-3.02%+13.83%+93.17% 40.36B
+3.22%+4.30%+227.37%+776.49% 41.63B
+0.57%+24.09%+99.46%+84.11% 33.29B
-1.09%+0.69%+14.20%+45.26% 32.27B
-4.46%+9.98%-43.92%+320.28% 22.91B
Average -0.40%+3.79%+34.96%+150.49% 38.54B
Weighted average by Cap. -0.17%+2.16%+46.63%+160.20%

Financials

2026 *2027 *
Net sales - -
Net income -111M -99.49M -91.39M -83M -156M -10.55B -160M -1.09B -439M -5.57B -418M -409M -17.65B -139M -124M -114M -103M -194M -13.12B -199M -1.36B -546M -6.93B -520M -509M -21.95B
Net Debt -424M -379M -348M -316M -593M -40.16B -608M -4.15B -1.67B -21.2B -1.59B -1.56B -67.19B -306M -273M -251M -228M -428M -28.94B -438M -2.99B -1.2B -15.28B -1.15B -1.12B -48.42B
Projected Income Statement - Annual - Avalo Therapeutics, Inc.
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
03/11/26 US$7.250 -0.96% 1,826,280
02/11/26 US$7.320 +2.09% 1,618,575
30/10/26 US$7.170 -3.63% 1,534,540
29/10/26 US$7.440 +4.49% 2,274,214
28/10/26 US$7.120 +5.48% 2,167,454
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avalo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
7.250USD
Average target price
36.60USD
Spread / Average Target
+404.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Avalo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AVTX Stock